Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Jia-Hao Zheng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0004-1554-4737; OpenAlex author ID A5021622620. Sources: OpenAlex.

Their work

Papers
13 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
35
Papers, trials and grants by year

2022: 3 papers · 2023: 4 papers · 2024: 5 papers · 2025: none · 2026: 1 paper

Papers 13

  1. L-Lactate reprograms tumor-associated macrophages to drive pancreatic cancer progression via BCL3 lactylation First author DOI 10.64898/2026.03.06.710237↗
  2. AGFG1 increases cholesterol biosynthesis by disrupting intracellular cholesterol homeostasis to promote PDAC progression. Co-author DOI 10.1016/j.canlet.2024.217130↗
  3. A CLIC1 network coordinates matrix stiffness and the Warburg effect to promote tumor growth in pancreatic cancer. Co-author DOI 10.1016/j.celrep.2024.114633↗
  4. OCIAD2 promotes pancreatic cancer progression through the AKT signaling pathway. Co-author DOI 10.1016/j.gene.2024.148735↗
  5. Oncogenic GALNT5 confers FOLFIRINOX resistance via activating the MYH9/ NOTCH/ DDR axis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41419-024-07110-w↗
  6. The lncRNA LINC01605 promotes the progression of pancreatic ductal adenocarcinoma by activating the mTOR signaling pathway. Co-author DOI 10.1186/s12935-024-03440-z↗
  7. Analysis of cuproptosis-related lncRNA signature for predicting prognosis and tumor immune microenvironment in pancreatic cancer. Co-author DOI 10.1007/s10495-023-01843-3↗
  8. Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironment. First author DOI 10.1007/s13402-022-00741-1↗
  9. Increased SPRY1 expression activates NF-κB signaling and promotes pancreatic cancer progression by recruiting neutrophils and macrophages through CXCL12-CXCR4 … Co-author DOI 10.1007/s13402-023-00791-z↗
  10. ADAMTS12 promotes migration and epithelial-mesenchymal transition and predicts poor prognosis for pancreatic cancer. First author DOI 10.1016/j.hbpd.2022.04.005↗
  11. IRAK2-NF-κB signaling promotes glycolysis-dependent tumor growth in pancreatic cancer. Co-author DOI 10.1007/s13402-022-00670-z↗
  12. Increased SPON1 promotes pancreatic ductal adenocarcinoma progression by enhancing IL-6 trans-signalling. Co-author DOI 10.1111/cpr.13237↗
  13. GJB3 promotes pancreatic cancer liver metastasis by enhancing the polarization and survival of neutrophil. Co-author DOI 10.3389/fimmu.2022.983116↗

Closest collaborators

The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yongwei Sun · 10 shared papers, 2022–2024 · strength 1.69
  2. Hong‐Fei Yao · 10 shared papers, 2022–2024 · strength 1.67
  3. Yan‐Miao Huo · 10 shared papers, 2022–2024 · strength 1.64
  4. Zong‐Hao Duan · 7 shared papers, 2023–2024 · strength 1.26
  5. Qin-Yuan Jia · 7 shared papers, 2023–2024 · strength 1.24
  6. Minwei Yang · 7 shared papers, 2022–2026 · strength 1.20
  7. Jian‐Yu Yang · 6 shared papers, 2022–2026 · strength 1.01
  8. Shu‐Heng Jiang · 5 shared papers, 2022–2026 · strength 0.90
  9. Yu-Heng Zhu · 5 shared papers, 2023–2024 · strength 0.89
  10. Xueliang Fu · 5 shared papers, 2022–2026 · strength 0.83
  11. Dejun Liu · 5 shared papers, 2022–2024 · strength 0.81
  12. Yifan Yin · 4 shared papers, 2024 · strength 0.73
  13. Li-Peng Hu · 4 shared papers, 2022–2024 · strength 0.63
  14. Rong Hua · 4 shared papers, 2022–2024 · strength 0.62
  15. Ruizhe He · 3 shared papers, 2022–2023 · strength 0.47
  16. Jian Yang · 3 shared papers, 2022–2024 · strength 0.46
  17. Pei‐Xuan Ji · 2 shared papers, 2024–2026 · strength 0.42
  18. Wei Liu · 2 shared papers, 2024 · strength 0.35
  19. Linli Yao · 2 shared papers, 2023–2024 · strength 0.35
  20. Dejun Liu · 2 shared papers, 2024 · strength 0.35
  21. Dapeng Xu · 2 shared papers, 2022–2023 · strength 0.32
  22. Junfeng Zhang · 2 shared papers, 2022–2023 · strength 0.28
  23. Yong-Wei Sun · 1 shared paper, 2026 · strength 0.24
  24. Wei Liu · 1 shared paper, 2024 · strength 0.20
  25. Wei Liu · 1 shared paper, 2024 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.